Developments in SPR Fragment Screening

References

• Erlanson DA, Jahnke W, Mannhold R, et al. Fragment-based drug discovery: lessons and outlook. Hoboken (NJ): John Wiley & Sons; 2016. p. 524.
   Google Scholar
• Retra K, Irth H, Van Muijlwijk-Koezen JE. Surface plasmon resonance biosensor analysis as a useful tool in FBDD. Drug Discov Today Technol. 2010;7(3):e181–7.
   Google Scholar
• Erlanson D, Zarlter T Fragments in the clinic: 2015 edition [Internet]. Practical Fragments. 2015. Available from: http://practicalfragments.blogspot.fr/2015/01/fragments-in-clinic-2015-edition.html
   Google Scholar
• Murray CW, Rees DC. The rise of fragment-based drug discovery. Nat Chem. 2009;1(3):187–192.
   PubMed Web of Science ®Google Scholar
• Kenny PW, Leitão A, Montanari CA. Ligand efficiency metrics considered harmful. J Comput Aided Mol Des. 2014;28(7):699–710.
   PubMed Web of Science ®Google Scholar
• Kenny P Molecular Design: Rule of Three considered harmful? [Internet]. [cited 2015 Nov 10]. Available from: http://fbdd-lit.blogspot.fr/2011/01/rule-of-three-considered-harmful.html
   Google Scholar
• Elinder M, Geitmann M, Gossas T, et al. Experimental validation of a fragment library for lead discovery using SPR biosensor technology. J Biomol Screen. 2011;16(1):15–25.
   PubMed Web of Science ®Google Scholar
• Karlsson R, Fält A. Experimental design for kinetic analysis of protein-protein interactions with surface plasmon resonance biosensors. J Immunol Methods. 1997;200(1–2):121–133.
   PubMed Web of Science ®Google Scholar
• Abdiche Y, Malashock D, Pinkerton A, et al. Determining kinetics and affinities of protein interactions using a parallel real-time label-free biosensor, the Octet. Anal Biochem. 2008;377(2):209–217.
   PubMed Web of Science ®Google Scholar
• Rich RL, Myszka DG. Kinetic analysis and fragment screening with Fujifilm AP-3000. Anal Biochem. 2010;402(2):170–178.
   PubMed Web of Science ®Google Scholar
• Rich RL, Quinn JG, Morton T, et al. Biosensor-based fragment screening using FastStep injections. Anal Biochem. 2010;407(2):270–277.
   PubMed Web of Science ®Google Scholar
• Rich RL, Myszka DG. Why you should be using more SPR biosensor technology. Drug Discov Today Technol. 2004;1(3):301–308.
   PubMedGoogle Scholar
• Navratilova I, Hopkins AL. Emerging role of surface plasmon resonance in fragment-based drug discovery. Future Med Chem. 2011;3(14):1809–1820.
   PubMed Web of Science ®Google Scholar
• Hämäläinen MD, Zhukov A, Ivarsson M, et al. Label-free primary screening and affinity ranking of fragment libraries using parallel analysis of protein panels. J Biomol Screen. 2008;13(3):202–229.
   PubMed Web of Science ®Google Scholar
• Boettcher A, Ruedisser S, Erbel P, et al. Fragment-based screening by biochemical assays: systematic feasibility studies with trypsin and MMP12. J Biomol Screen. 2010;15(9):1029–41.
   PubMed Web of Science ®Google Scholar
• Nordström H, Gossas T, Hämäläinen M, et al. Identification of MMP-12 inhibitors by using biosensor-based screening of a fragment library. J Med Chem. 2008;51(12):3449–3459.
   PubMed Web of Science ®Google Scholar
• Pollack SJ, Beyer KS, Lock C, et al. A comparative study of fragment screening methods on the p38α kinase: new methods, new insights. J Comput Aided Mol Des. 2011;25(7):677–687.
   PubMed Web of Science ®Google Scholar
• Shepherd CA, Hopkins AL, Navratilova I. Fragment screening by SPR and advanced application to GPCRs. Prog Biophys Mol Biol. 2014;116(2–3):113–123.
   PubMed Web of Science ®Google Scholar
• Aristotelous T, Ahn S, Shukla AK, et al. Discovery of β2 adrenergic receptor ligands using biosensor fragment screening of tagged wild-type receptor. ACS Med Chem Lett. 2013;4(10):1005–1010.
   PubMed Web of Science ®Google Scholar
• Bower JF, Pannifer A. Using fragment-based technologies to target protein-protein interactions. Curr Pharm Des. 2012;18(30):4685–4696.
   PubMed Web of Science ®Google Scholar
• Rouhana J, Hoh F, Estaran S, et al. Fragment-based identification of a locus in the Sec7 domain of Arno for the design of protein-protein interaction inhibitors. J Med Chem. 2013;56(21):8497–8511.
   PubMed Web of Science ®Google Scholar
• Hennig M, Ruf A, Huber W. Combining biophysical screening and X-ray crystallography for fragment-based drug discovery. Top Curr Chem. 2012;317:115–143.
   PubMed Web of Science ®Google Scholar
• Giannetti AM. From experimental design to validated hits a comprehensive walk-through of fragment lead identification using surface plasmon resonance. Methods Enzymol. 2011;493:169–218.
   PubMed Web of Science ®Google Scholar
• Karlsson R. SPR for molecular interaction analysis: a review of emerging application areas. J Mol Recognit JMR. 2004;17(3):151–161.
   PubMed Web of Science ®Google Scholar
• Kretschmann E. Decay of non radiative surface plasmons into light on rough silver films. Comparison of experimental and theoretical results. Opt Commun. 1972;6(2):185–187.
   Google Scholar
• SPR Instruments [Internet]. [cited 2016 Feb 26]. Available from: http://www.sprpages.nl/instruments
   Google Scholar
• Neumann T, Junker H-D, Schmidt K, el al SPR-based fragment screening: advantages and applications. Curr Top Med Chem. 2007;7(16):1630–1642.
   PubMed Web of Science ®Google Scholar
• Quinn JG. Evaluation of Taylor dispersion injections: determining kinetic/affinity interaction constants and diffusion coefficients in label-free biosensing. Anal Biochem. 2012;421(2):401–410.
   PubMed Web of Science ®Google Scholar
• Giannetti AM, Gilbert HN, Huddler DP, et al. CHAPTER 2. In: CHAPTER 2: Getting the Most Value from Your Screens: Advances in Hardware, Software, and Methodologies to Enhance Surface Plasmon Resonance Based Fragment Screening and Hit-to-Lead Support [Internet]. 2015 [cited 2015 Nov 18]. Available from: http://pubs.rsc.org/en/content/chapter/bk9781849739085-00019/978-1-84973-908-5.
   Google Scholar
• FBLD_Application_Note.pdf [Internet]. [cited 2015 Nov 26]. Available from: https://www.sensiqtech.com/uploads/file/applications/FBLD_Application_Note.pdf
   Google Scholar
• Patching SG. Surface plasmon resonance spectroscopy for characterisation of membrane protein-ligand interactions and its potential for drug discovery. Biochim Biophys Acta. 2014;1838(1 Pt A):43–55.
   PubMed Web of Science ®Google Scholar
• Maynard JA, Lindquist NC, Sutherland JN, et al. Surface plasmon resonance for high-throughput ligand screening of membrane-bound proteins. Biotechnol J. 2009;4(11):1542–1558.
   PubMedGoogle Scholar
• Papalia G, Myszka D. Exploring minimal biotinylation conditions for biosensor analysis using capture chips. Anal Biochem. 2010;403(1–2):30–35.
   PubMed Web of Science ®Google Scholar
• Congreve M, Rich RL, Myszka DG, et al. Fragment screening of stabilized G-protein-coupled receptors using biophysical methods. Methods Enzymol. 2011;493:115–136.
   PubMed Web of Science ®Google Scholar
• Hennig M, Ruf A, Huber W. Combining biophysical screening and X-ray crystallography for fragment-based drug discovery. Top Curr Chem. 2012;317:115–143.
   PubMed Web of Science ®Google Scholar
• Giannetti AM, Koch BD, Browner MF. Surface plasmon resonance based assay for the detection and characterization of promiscuous inhibitors. J Med Chem. 2008;51(3):574–580.
   PubMed Web of Science ®Google Scholar
• McGovern SL, Helfand BT, Feng B, et al. A specific mechanism of nonspecific inhibition. J Med Chem. 2003;46(20):4265–4272.
   PubMed Web of Science ®Google Scholar
• Perspicace S, Banner D, Benz J, et al. Fragment-based screening using surface plasmon resonance technology. J Biomol Screen. 2009;14(4):337–349.
   PubMed Web of Science ®Google Scholar
• Giannetti AM, Zheng X, Skelton NJ, et al. Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT). J Med Chem. 2014;57(3):770–792.
   PubMed Web of Science ®Google Scholar
• Karlsson R, Kullman-Magnusson M, et al. Biosensor analysis of drug-target interactions: direct and competitive binding assays for investigation of interactions between thrombin and thrombin inhibitors. Anal Biochem. 2000;278(1):1–13.
   PubMed Web of Science ®Google Scholar
• Pfaff SJ, Chimenti MS, Kelly MJS, et al. Biophysical methods for identifying fragment-based inhibitors of protein-protein interactions. Methods Mol Biol Clifton NJ. 2015;1278:587–613.
   PubMedGoogle Scholar
• Harner MJ, Frank AO, Fesik SW. Fragment-based drug discovery using NMR spectroscopy. J Biomol NMR. 2013;56(2):65–75.
   PubMed Web of Science ®Google Scholar
• Dalvit C. NMR methods in fragment screening: theory and a comparison with other biophysical techniques. Drug Discov Today. 2009;14(21–22):1051–1057.
   PubMed Web of Science ®Google Scholar
• Patel D, Bauman JD, Arnold E. Advantages of crystallographic fragment screening: functional and mechanistic insights from a powerful platform for efficient drug discovery. Prog Biophys Mol Biol. 2014;116(2–3):92–100.
   PubMed Web of Science ®Google Scholar
• Meyer B, Klein J, Mayer M, et al. Saturation transfer difference NMR spectroscopy for identifying ligand epitopes and binding specificities. Ernst Scher Res Found Workshop. 2004;(44):149–167.
   PubMedGoogle Scholar
• Dalvit C, Pevarello P, Tatò M, et al. Identification of compounds with binding affinity to proteins via magnetization transfer from bulk water. J Biomol NMR. 2000;18(1):65–68.
   PubMed Web of Science ®Google Scholar
• Shuker SB, Hajduk PJ, Meadows RP, et al. Discovering high-affinity ligands for proteins: SAR by NMR. Science. 1996;274(5292):1531–1534.
   PubMed Web of Science ®Google Scholar
• Maurer T. Advancing fragment binders to lead-like compounds using ligand and protein-based NMR spectroscopy. Methods Enzymol. 2011;493:469–485.
   PubMed Web of Science ®Google Scholar
• Manjasetty BA, Turnbull AP, Panjikar S, et al. Automated technologies and novel techniques to accelerate protein crystallography for structural genomics. Proteomics. 2008;8(4):612–625.
   PubMed Web of Science ®Google Scholar
• Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there? Nat Rev Drug Discov. 2006;5(12):993–996.
   PubMed Web of Science ®Google Scholar
• Congreve M, Langmead CJ, Mason JS, et al. Progress in structure based drug design for g protein-coupled receptors. J Med Chem. 2011;54(13):4283–4311.
   PubMed Web of Science ®Google Scholar
• Christopher JA, Brown J, Doré AS, et al. Biophysical fragment screening of the β1-adrenergic receptor: identification of high affinity arylpiperazine leads using structure-based drug design. J Med Chem. 2013;56:3446–3455.
   PubMed Web of Science ®Google Scholar
• Robertson N, Jazayeri A, Errey J, et al. The properties of thermostabilised G protein-coupled receptors (StaRs) and their use in drug discovery. Neuropharmacology. 2011;60(1):36–44.
   PubMed Web of Science ®Google Scholar
• Navratilova I, Besnard J, Hopkins AL. Screening for GPCR ligands using surface plasmon resonance. ACS Med Chem Lett. 2011;2(7):549–554.
   PubMed Web of Science ®Google Scholar
• Wallace TL, Porter RHP. Targeting the nicotinic alpha7 acetylcholine receptor to enhance cognition in disease. Biochem Pharmacol. 2011;82(8):891–903.
   PubMed Web of Science ®Google Scholar
• Spurny R, Debaveye S, Farinha A, et al. Molecular blueprint of allosteric binding sites in a homologue of the agonist-binding domain of the α7 nicotinic acetylcholine receptor. Proc Natl Acad Sci U S A. 2015;112(19):E2543–52.
   PubMed Web of Science ®Google Scholar
• Grädler U, Bomke J, Musil D, et al. Fragment-based discovery of focal adhesion kinase inhibitors. Bioorg Med Chem Lett. 2013;23(19):5401–5409.
   PubMed Web of Science ®Google Scholar
• Nordström H, Gossas T, Hämäläinen M, et al. Identification of MMP-12 inhibitors by using biosensor-based screening of a fragment library. J Med Chem. 2008;51(12):3449–3459.
   PubMed Web of Science ®Google Scholar
• Boettcher A, Ruedisser S, Erbel P, et al. Fragment-based screening by biochemical assays: systematic feasibility studies with trypsin and MMP12. J Biomol Screen. 2010;15:1029–1041.
   PubMed Web of Science ®Google Scholar
• Fischer G, Rossmann M, Hyvönen M. Alternative modulation of protein-protein interactions by small molecules. Curr Opin Biotechnol. 2015;35:78–85.
   PubMed Web of Science ®Google Scholar
• Magee TV. Progress in discovery of small-molecule modulators of protein-protein interactions via fragment screening. Bioorg Med Chem Lett. 2015;25(12):2461–2468.
   PubMed Web of Science ®Google Scholar
• Smith MC, Gestwicki JE. Features of protein-protein interactions that translate into potent inhibitors: topology, surface area and affinity. Expert Rev Mol Med. 2012;14:e16.
   PubMed Web of Science ®Google Scholar
• Valkov E, Sharpe T, Marsh M, et al. Targeting protein-protein interactions and fragment-based drug discovery. Top Curr Chem. 2012;317:145–179.
   PubMed Web of Science ®Google Scholar
• Thangudu RR, Bryant SH, Panchenko AR, et al. Modulating protein-protein interactions with small molecules: the importance of binding hotspots. J Mol Biol. 2012;415(2):443–453.
   PubMed Web of Science ®Google Scholar
• Wiley: Small Molecule Medicinal Chemistry: Strategies and Technologies - Werngard Czechtizky, Peter Hamley [Internet]. [cited 2015 Dec 20]. Available from: http://eu.wiley.com/WileyCDA/WileyTitle/productCd-1118771605,subjectCd-CH80.html
   Google Scholar
• Kuo LC. Fragment-based drug design: tools, practical approaches, and examples. San Diego (CA): Academic Press; 2011. p. 662.
   Google Scholar
• Day YSN, Baird CL, Rich RL, et al. Direct comparison of binding equilibrium, thermodynamic, and rate constants determined by surface- and solution-based biophysical methods. Protein Sci Publ Protein Soc. 2002;11(5):1017–1025.
   PubMed Web of Science ®Google Scholar
• Wielens J, Headey SJ, Rhodes DI, et al. Parallel screening of low molecular weight fragment libraries: do differences in methodology affect hit identification? J Biomol Screen. 2013;18(2):147–159.
   PubMed Web of Science ®Google Scholar
• Konteatis ZD. In silico fragment-based drug design. Expert Opin Drug Discov. 2010;5(11):1047–1065.
   PubMed Web of Science ®Google Scholar
• Erlanson DA. Introduction to fragment-based drug discovery. Top Curr Chem. 2012;317:1–32.
   PubMed Web of Science ®Google Scholar
• de Kloe GE, Retra K, Geitmann M, et al. Surface plasmon resonance biosensor based fragment screening using acetylcholine binding protein identifies ligand efficiency hot spots (LE hot spots) by deconstruction of nicotinic acetylcholine receptor α7 ligands. J Med Chem. 2010;53(19):7192–7201.
   PubMed Web of Science ®Google Scholar
• Wu B, Barile E, De SK, et al. High-throughput screening by nuclear magnetic resonance (HTS by NMR) for the identification of PPIs antagonists. Curr Top Med Chem. 2015;15(20):2032–2042.
   PubMed Web of Science ®Google Scholar